Tenaya Therapeutics (TNYA) Research & Development (2020 - 2026)
Tenaya Therapeutics (TNYA) posted quarterly Research & Development of $14.8 million for Q1 2026, down 29.57% year-over-year from $21.1 million in Q1 2025, and little changed quarter-over-quarter from $14.8 million in Q4 2025.
Tenaya Therapeutics (TNYA) Research & Development (2020 - 2026) Analysis & Trends
Tenaya Therapeutics' Research & Development history runs 7 years deep, the most recent figure standing at $14.8 million for Q1 2026.
- In Q1 2026, Research & Development fell 29.57% year-over-year to $14.8 million; the TTM figure through Mar 2026 stood at $62.4 million (down 24.64% YoY), while the FY2025 annual figure was $68.6 million, down 20.91% from the prior year.
- Research & Development for Q1 2026 stood at $14.8 million, roughly flat from $14.8 million in the prior quarter.
- The five-year high for Research & Development was $26.5 million in Q2 2023, with the low at $14.8 million in Q4 2025.
- The 5-year median for Research & Development is $22.6 million (2024), against an average of $21.3 million.
- The sharpest annual moves came in 2022 and 2026: Research & Development surged 151.88% in 2022, then decreased 29.57% in 2026.
- Tenaya Therapeutics' Research & Development stood at $25.7 million in 2022, then retreated by 11.2% to $22.9 million in 2023, then retreated by 18.27% to $18.7 million in 2024, then fell by 20.82% to $14.8 million in 2025, then increased by 0.3% to $14.8 million in 2026.
- Business Quant data shows TNYA's Research & Development at $14.8 million in Q1 2026, $14.8 million in Q4 2025, and $15.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Tenaya Therapeutics | 150.58 Mn | 150.58 Mn | - | 16.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.60 Mn |
| Mar 31, 2026 | 14.84 Mn |
| Dec 31, 2025 | 14.80 Mn |
| Sep 30, 2025 | 15.36 Mn |
| Jun 30, 2025 | 17.37 Mn |
| Mar 31, 2025 | 21.08 Mn |
| Dec 31, 2024 | 18.69 Mn |
| Sep 30, 2024 | 20.35 Mn |
| Jun 30, 2024 | 22.65 Mn |
| Mar 31, 2024 | 25.06 Mn |
| Dec 31, 2023 | 22.87 Mn |
| Sep 30, 2023 | 23.09 Mn |
| Jun 30, 2023 | 26.48 Mn |
| Mar 31, 2023 | 25.61 Mn |
| Dec 31, 2022 | 25.75 Mn |
| Sep 30, 2022 | 23.76 Mn |
| Jun 30, 2022 | 20.88 Mn |
| Mar 31, 2022 | 24.16 Mn |
| Dec 31, 2021 | 20.95 Mn |
| Sep 30, 2021 | 12.94 Mn |